AARD vs MDLZ · $284.4M cap vs P/E 30, rev $38.54B
Aardvark Therapeutics, Inc. Common Stock (AARD) versus Mondelez International Inc (MDLZ) — a side-by-side from cached financials, not a winner call.
Aardvark Therapeutics, Inc. Common Stock (AARD) is a biotechnology company listed on US.
Mondelez International Inc (MDLZ) is a confectioners company listed on NASDAQ.
Latest reported AARD revenue for 2025-12-31 was $0. Net income was -$57.6M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. AARD currently screens at market cap $284.4M.
Latest reported MDLZ revenue for 2025-12-31 was $38.54B. Net income was $2.45B. Revenue was up 5.8% from 2024-12-31 to 2025-12-31. MDLZ currently screens at market cap $78.12B and trailing P/E 30.1.
AARD currently screens at market cap $284.4M. MDLZ currently screens at market cap $78.12B and trailing P/E 30.1.
Not investment advice. Open the AARD and MDLZ stock pages for the full models.
Not investment advice.